Literature DB >> 17803727

Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration.

E Lallemand1, A Lespine, M Alvinerie, A Bousquet-Melou, P-L Toutain.   

Abstract

Moxidectin is a long-acting anthelmintic drug for which little is known about its kinetic behaviour in dogs and its oral absolute bioavailability has never been reported. We studied the pharmacokinetics of moxidectin in dogs, with a special emphasis on oral bioavailability and the influence of lipid co-administration, by using a semi-simultaneous method of administration. Ten Beagle dogs were dosed orally and then intravenously (i.v.) with 0.2 mg/kg moxidectin. The oral application was conducted with or without corn oil co-administration. Moxidectin concentration-time profiles in plasma were analysed using a compartmental modelling approach, designed to fit the oral and i.v. kinetic disposition curves simultaneously. In contrast to what happens in other species, our study indicates that the bioavailability of orally given moxidectin in dogs is nearly total (90.2 +/- 7.4%), and is not enhanced by lipid co-administration. The clearance, the volume of distribution, the mean residence time and the terminal half-life were similar to what was already described for other species. Finally our trial suggests that the body condition (degree of obesity) is likely to be a major determinant of moxidectin kinetics in dogs because of its modulation of the volume of distribution that indirectly controls the terminal half-life of the drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803727     DOI: 10.1111/j.1365-2885.2007.00878.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  6 in total

Review 1.  How do the macrocyclic lactones kill filarial nematode larvae?

Authors:  Adrian J Wolstenholme; Mary J Maclean; Ruby Coates; Ciaran J McCoy; Barbara J Reaves
Journal:  Invert Neurosci       Date:  2016-06-09

Review 2.  Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats.

Authors:  Valentina M Merola; Paul A Eubig
Journal:  Vet Clin North Am Small Anim Pract       Date:  2012-03       Impact factor: 2.093

3.  Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women.

Authors:  Joan M Korth-Bradley; Virginia Parks; Stephan Chalon; Ian Gourley; Kyle Matschke; Sophie Gossart; Philip Bryson; Lawrence Fleckenstein
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

4.  Preventive efficacy of oral moxidectin at various doses and dosage regimens against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs.

Authors:  Tom L McTier; Robert H Six; Aleah Pullins; Sara Chapin; Kristina Kryda; Sean P Mahabir; Debra J Woods; Steven J Maeder
Journal:  Parasit Vectors       Date:  2019-09-11       Impact factor: 3.876

5.  A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.

Authors:  Alain Bousquet-Mélou; Anne Lespine; Jean-François Sutra; Isabelle Bargues; Pierre-Louis Toutain
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

6.  Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs.

Authors:  Kristina Kryda; Robert H Six; Kelly F Walsh; Susan J Holzmer; Sara Chapin; Sean P Mahabir; Melanie Myers; Tammy Inskeep; Jady Rugg; Blair Cundiff; Aleah Pullins; Michael Ulrich; John W McCall; Tom L McTier; Steven J Maeder
Journal:  Parasit Vectors       Date:  2019-09-11       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.